In a recent commentary,1 Miller and Shorr discuss generally the use of placebo controls when there is an existing effective treatment and then consider specifically 3 recent placebo-controlled studies in asthma, all of which they believe did not need to use a placebo. In at least 1 of the 3 studies, the issue is more complex than they allow.
The authors note the recent increased interest in the ethics of the use of placebo controls provoked by the 2000 revision of the Declaration of Helsinki,2 which said such controls were not appropriate when there was existing effective therapy. Miller and Shorr clearly recognize, however, the interpretive problems often posed by active control equivalence or noninferiority trials3- 5 and thus the continued need for placebo controls in many situations, even when there is existing therapy. Indeed, a commentary on the 2000 revision by the World Medical Association in 20016 indicates similar recognition, so long as use of the placebo instead of available therapy does not expose patients to serious harm. Miller and Shorr divide placebo considerations into the following 3 categories: (1) when failure to use available therapy exposes patients to risk of death, irreversible harm, or intolerable discomfort (placebo is clearly unacceptable in such cases); (2) when the condition causes only mild to moderate discomfort (headache, allergic rhinitis, and/or heartburn) and patients frequently forgo treatment (there is no ethical impediment to use of placebo in such cases); (3) when the illnesses are more serious and discomfort associated with nontreatment is more severe, but methodological considerations call for use of a placebo and the study is designed to minimize discomfort. It is into this last category that the authors place asthma, along with angina, migraine headaches, and depression. Although studies of those conditions require attention to patient selection and study design (in case of worsening), that should not lead to the conclusion that placebo controls are not needed in those cases.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.